• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Trifluridine/tipiracil in earlier lines of chemotherapy for advanced colorectal cancer.

作者信息

Roda D, Roselló S, Huerta M, Cervantes A

机构信息

Department Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.

Department Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.

出版信息

Ann Oncol. 2020 Sep;31(9):1097-1098. doi: 10.1016/j.annonc.2020.05.030. Epub 2020 Jun 13.

DOI:10.1016/j.annonc.2020.05.030
PMID:32544547
Abstract
摘要

相似文献

1
Trifluridine/tipiracil in earlier lines of chemotherapy for advanced colorectal cancer.
Ann Oncol. 2020 Sep;31(9):1097-1098. doi: 10.1016/j.annonc.2020.05.030. Epub 2020 Jun 13.
2
Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.新型三联疗法曲氟尿苷/替匹嘧啶联合贝伐单抗用于意大利转移性结直肠癌三线治疗的成本效益分析
Clin Colorectal Cancer. 2024 Mar;23(1):1-3. doi: 10.1016/j.clcc.2023.10.005. Epub 2023 Oct 14.
3
Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.曲氟尿苷/替匹嘧啶联合贝伐单抗一线治疗转移性结直肠癌：前进之路。基于成本效益的观点
Clin Colorectal Cancer. 2022 Jun;21(2):e145-e147. doi: 10.1016/j.clcc.2021.11.012. Epub 2021 Dec 5.
4
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.回顾性队列研究：替氟尿苷/盐酸拓扑替康（TAS-102）联合贝伐珠单抗对比替氟尿苷/盐酸拓扑替康单药治疗转移性结直肠癌。
BMC Cancer. 2019 Dec 27;19(1):1253. doi: 10.1186/s12885-019-6475-6.
5
[Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].[使用曲氟尿苷/替匹嘧啶作为晚期化疗方案的复发性胃癌长期存活者]
Gan To Kagaku Ryoho. 2020 Dec;47(13):2056-2058.
6
The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.替氟尿苷他比嘧啶治疗转移性结直肠癌的安全性和有效性：药剂学视角。
Am J Health Syst Pharm. 2019 Feb 21;76(6):339-348. doi: 10.1093/ajhp/zxy006.
7
Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.奥沙利铂联合替匹嘧啶/三氟尿苷治疗转移性结直肠癌的 I 期剂量递增研究。
Eur J Cancer. 2019 May;112:12-19. doi: 10.1016/j.ejca.2019.01.101. Epub 2019 Mar 16.
8
First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.一线替氟尿苷/替匹嘧啶联合贝伐珠单抗治疗不可切除转移性结直肠癌：SOLSTICE 研究设计。
Future Oncol. 2020 Feb;16(4):21-29. doi: 10.2217/fon-2019-0786. Epub 2020 Jan 9.
9
Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer: from clinical trials to daily clinical practice.曲氟尿苷/替匹嘧啶或瑞戈非尼用于难治性转移性结直肠癌：从临床试验到日常临床实践
Recenti Prog Med. 2020 Dec;111(12):785-787. doi: 10.1701/3509.34971.
10
Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real Life.曲氟尿苷/替匹嘧啶在现实生活中治疗难治性转移性结直肠癌的经济可持续性
Clin Colorectal Cancer. 2020 Dec;19(4):e181-e182. doi: 10.1016/j.clcc.2020.04.004. Epub 2020 Apr 23.

引用本文的文献

1
Integrative approach using network pharmacology, bioinformatics, and experimental methods to explore the mechanism of cantharidin in treating colorectal cancer.采用网络药理学、生物信息学和实验方法的综合方法探讨斑蝥素治疗结直肠癌的作用机制。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):6745-6761. doi: 10.1007/s00210-024-03041-7. Epub 2024 Mar 20.
2
Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment.免疫疗法能否增强化疗疗效？结直肠癌治疗的新视角。
Front Immunol. 2023 Sep 18;14:1237764. doi: 10.3389/fimmu.2023.1237764. eCollection 2023.